A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

The expected revenue total includes $3.5 billion in sales of diabetes treatment Mounjaro, which is below the FactSet consensus of $4.4 billion, and $1.9 billion in sales of weight-loss drug Zepbound, ...

Big Pharma is hiding a massive secret about so-called miracle weight-loss drugs like Ozempic – they come with a raft of ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

As for its other main weight-loss drug, Zepbound, the firm estimated that it had brought in $1.9 billion, versus the mean ...

Ozempic, inflation and the Trump presidency will likely dictate food waste trends in the US in 2025, according to non-profit ...